Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis

TY - JOUR

T1 - Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis

AU - Frøling, Malte

AU - Mikkelsen, Clara

AU - Eggertsen, Peter Preben

AU - Stern, Mette

AU - van de Looij, Anne

AU - Deleuran, Bent

PY - 2017/10/30

Y1 - 2017/10/30

N2 - Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. The introduction of a new class of disease-modifying anti-rheumatic drugs, which work by inhibiting the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway, has led to new possibilities for achieving remission of RA. Tofacitinib and baricitinib are both JAK/STAT inhibitors, which have shown efficacy in line with anti-tumour necrosis factor treatment. The side effects seem manageable, and up to now only increased risk of herpes zoster has raised consideration. JAK/STAT inhibitors create new possibilities for reaching low disease activity or remission for patients with RA.

AB - Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. The introduction of a new class of disease-modifying anti-rheumatic drugs, which work by inhibiting the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway, has led to new possibilities for achieving remission of RA. Tofacitinib and baricitinib are both JAK/STAT inhibitors, which have shown efficacy in line with anti-tumour necrosis factor treatment. The side effects seem manageable, and up to now only increased risk of herpes zoster has raised consideration. JAK/STAT inhibitors create new possibilities for reaching low disease activity or remission for patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=85060141367&partnerID=8YFLogxK

M3 - Review

C2 - 29084618

AN - SCOPUS:85060141367

SN - 0041-5782

VL - 179

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 44

ER -